Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
|Articles|March 14, 2017
Aptar Pharma launches eDose Counter for MDIs integrating a proprietary sensing technology
Author(s)Aptar Pharma
Advertisement
eDose Counter for MDIs
Picture courtesy of Aptar Pharma
Aptar Pharma unveils its eDose Counter for metered dose inhalers (MDIs). Our patented eDose Counter for MDIs is designed to be easy-to-use and reliable, and contributes to patient compliance. Our unique sensing technology offers direct detection of the spray, which eliminates risks of miscounting. The sensing technology is versatile and compatible with any metering valve design. In addition, our eDose Counter for MDIs includes inhaler priming and medication reminders-to-use and end-of-product-life warnings (flashing digits) while remaining cost-effective.
For further information, visit
About Aptar Pharma
Aptar Pharma is part of the AptarGroup, Inc. family of companies, along with Aptar Beauty + Home and Aptar Food + Beverage.
The company creates innovative drug delivery systems that meet the evolving needs of biotechnology, healthcare and pharmaceutical companies around the world.
Aptar Pharma provides customers with a wide range of delivery technologies and analytical services backed by decades of proven expertise.
AptarGroup is headquartered in Crystal Lake, Illinois, United States, with manufacturing facilities in North America, Europe, Asia and South America.
For more information, visit
Advertisement
Related to this article
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Ron Scarboro, Azurity Pharmaceuticals, claims drug reformulation that removes patient barriers must preserve efficacy, urging early cross-functional team alignment.
PharmTech AI Pulse Check episode 2 covers AI data governance, API-gated journals, watermarking limits, and why attribution beats detection in GxP.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Novartis licenses Abogen's mRNA-encoded T-cell engager for autoimmune disease, raising scale-up questions for mRNA-lipid nanoparticle manufacturing.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Advertisement
Advertisement